Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

ImmunityBio (IBRX) Equity Average (2016 - 2025)

ImmunityBio (IBRX) has disclosed Equity Average for 11 consecutive years, with -$512.4 million as the latest value for Q4 2025.

  • Quarterly Equity Average rose 16.84% to -$512.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$512.4 million through Dec 2025, up 16.84% year-over-year, with the annual reading at -$494.3 million for FY2025, 7.96% up from the prior year.
  • Equity Average for Q4 2025 was -$512.4 million at ImmunityBio, up from -$547.1 million in the prior quarter.
  • The five-year high for Equity Average was -$151.9 million in Q1 2021, with the low at -$720.8 million in Q3 2024.
  • Average Equity Average over 5 years is -$460.2 million, with a median of -$505.3 million recorded in 2023.
  • The sharpest move saw Equity Average plummeted 6850.95% in 2021, then grew 24.1% in 2025.
  • Over 5 years, Equity Average stood at -$216.9 million in 2021, then tumbled by 102.58% to -$439.5 million in 2022, then dropped by 13.39% to -$498.3 million in 2023, then decreased by 23.65% to -$616.1 million in 2024, then increased by 16.84% to -$512.4 million in 2025.
  • According to Business Quant data, Equity Average over the past three periods came in at -$512.4 million, -$547.1 million, and -$580.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.